IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision combination therapies. Inspired by a few curative combination regimens in cancer and the successful drug cocktails purposely engineered in other disease areas such as cystic fibrosis and antivirals, IDRx aims to address the limitations of today’s precision cancer medicines with highly -selective, purposely -designed drug combinations to help more patients achieve prolonged, durable responses to therapy earlier in the course of their disease. Founded in 2022, IDRx’s leadership team has extensive experience in drug development, and collectively has been involved in the discovery, development and commercialization of more than 10 approved drugs.
Location: United States, Massachusetts, Plymouth
Employees: 11-50
Total raised: $242M
Founded date: 2022
Funding Rounds 2
| Date | Series | Amount | Investors |
| 13.08.2024 | - | $120M | - |
| 06.08.2022 | Series A | $122M | - |
Mentions in press and media 6
| Date | Title | Description |
| 13.08.2024 | IDRx Raises $120 Million To Transform Cancer Treatment With Precision Therapies | IDRx (a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision therapies) announced the completion of an oversubscribed $120 million Series B Preferred Stock financing. This financin... |
| 09.08.2024 | The Week’s 10 Biggest Funding Rounds: Anduril Industries Raises Big For Defense | 7 Shares Email Facebook Twitter LinkedIn Want to keep track of the largest startup funding deals in 2024 with our curated list of $100 million-plus venture deals to U.S.-based companies? Check out The Crunchbase Megadeals Board. This is a w... |
| 29.11.2022 | Pitchbook’s Emerging Technology Indicator Reports Shows Q3 Deal Value Down | Pitchbooks new Emerging Technology Indicator report shows that Q3 deal value is down.getty |
| 02.08.2022 | IDRx Raises $122M in Series A Financing | IDRx, Inc., a Plymouth, MA-based clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision combination therapies, raised $122m in Series A financing. The round was led by Andreessen Hor... |
| - | Idrx | “Intelligently designed precision combinations to transform cancer care” |
| - | Aiming to bring drug combos into earlier lines of cancer therapy, IDRx lands $122M | A precision medicine is only as good as its target. While targeted therapies now address many types of cancer, tumors still frequently develop mutations that help them escape a drug. One strategy to address tumor escape is combining differe... |